Last $9.45 USD
Change Today -0.05 / -0.53%
Volume 804.1K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Open
$9.54
Previous Close
$9.50
Day High
$9.56
Day Low
$9.35
52 Week High
01/24/14 - $18.18
52 Week Low
04/28/14 - $6.88
Market Cap
1.2B
Average Volume 10 Days
795.3K
EPS TTM
$-0.71
Shares Outstanding
125.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALO)

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of pancreatic cancer; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; and Baxter Healthcare Corporation. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

170 Employees
Last Reported Date: 02/28/14
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $314.9K
Vice President, General Counsel and Secretary
Total Annual Compensation: $317.5K
Consultant
Total Annual Compensation: $366.7K
Compensation as of Fiscal Year 2013.

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Halozyme Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenues were $18,385,000 compared to $14,454,000 a year ago. Operating loss was $14,940,000 compared to $22,121,000 a year ago. Net loss was $16,273,000 compared to $22,912,000 a year ago. Basic and diluted net loss per share was $0.13 compared to $0.20 a year ago. For the six months, the company's total revenues were $30,351,000 compared to $26,287,000 a year ago. Operating loss was $40,159,000 compared to $40,617,000 a year ago. Net loss was $42,821,000 compared to $42,200,000 a year ago. Basic and diluted net loss per share was $0.35 compared to $0.38 a year ago.

Halozyme Therapeutics, Inc. to Report Q2, 2014 Results on Aug 11, 2014

Halozyme Therapeutics, Inc. announced that they will report Q2, 2014 results After-Market on Aug 11, 2014

Halozyme Therapeutics, Inc., Q2 2014 Earnings Call, Aug 11, 2014

Halozyme Therapeutics, Inc., Q2 2014 Earnings Call, Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $9.45 USD -0.05

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $12.00 USD -0.09
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.0x
Price/Book 21.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.